Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.43 |
| ▸ | CNR1 | P21554 | 4/20 | 0.43 |
| ▸ | CNR2 | P34972 | 4/20 | 0.43 |
| ▸ | GBA1 | P04062 | 2/20 | 0.40 |
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8444358 | 0.78 | PYGB (0.37) | — | |
| SCHEMBL29728301 | 0.78 | PYGB (0.37) | — | |
| SCHEMBL28360430 | 0.78 | EPHX2 (0.43) | EPHX2TRPV1CNR1CNR2GBA1 | |
| SCHEMBL28891560 | 0.78 | EPHX2 (0.43) | EPHX2TRPV1CNR1CNR2GBA1 | |
| SCHEMBL28364090 | 0.78 | EPHX2 (0.43) | EPHX2TRPV1CNR1CNR2GBA1 | |
| SCHEMBL8177748 | 0.71 | EPHX2 (0.33) | EPHX2TRPV1CNR1CNR2GBA1 | |
| SCHEMBL8170117 | 0.71 | EPHX2 (0.33) | EPHX2TRPV1CNR1CNR2GBA1 | |
| SCHEMBL16827171 | 0.69 | GBA1 (0.34) | GBA1 | |
| SCHEMBL8067513 | 0.67 | PRKCA (0.42) | PRKCA | |
| SCHEMBL7555303 | 0.66 | PRKCA (0.41) | GBA1PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557893-B2 | Substituted saccharide compounds and dental compositions | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557893-B2 | Substituted saccharide compounds and dental compositions | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-10-15 | — | — | US | disclosed |
| US-20130164709-A1 | SUBSTITUTED SACCHARIDE COMPOUNDS AND DENTAL COMPOSITIONS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130164709-A1 | SUBSTITUTED SACCHARIDE COMPOUNDS AND DENTAL COMPOSITIONS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130164709-A1 | SUBSTITUTED SACCHARIDE COMPOUNDS AND DENTAL COMPOSITIONS | SI, ACMSD, SORD | EPHX2 521/4885TRPV1 659/4885CNR1 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.